NEW YORK (TheStreet) -- RATINGS CHANGES
(BC) was upgraded at Keybanc to buy from hold. Twelve-month price target is $55. Product refresh should help grow the business, Keybanc said.
(COH) was downgraded at Bank of America/Merrill Lynch to underperform from neutral. Twelve-month price target was lowered to $31. Productivity is declining and consensus estimates appear as much as 23% too high, BofA/Merrill said.
(HOG - Get Report) was initiated with a sector perform rating at RBC Capital. Valuation call, based on a 12-month price target of $74, RBC said.
was upgraded at UBS to buy from neutral. Reflects building momentum for railcar order with company best positioned to increase production. Twelve-month price target is $51.
was downgraded at Wedbush to neutral from outperform. Twelve-month price target was lowered to $157. Estimates were also cut, because of low near-term visibility and new company guidance, Wedbush said.
was downgraded at HC Wainwright to neutral from buy. Twelve-month price target is $85. 809 drug still has scientific risks, HC Wainwright said.
was upgraded at Jefferies to buy from hold. Reflecting potential tax inversion, recap, and cost-cutting initiatives, Jefferies said. Twelve-month price target is $87.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
Follow TheStreet on Twitter and become a fan on Facebook
Flying Between the U.S. and China Is Booming; Too Bad It's Not Profitable
Why Barnes & Noble Stock Is Surging This Morning